Engineering of TIMP‐3 as a LAP‐fusion protein for targeting to sites of inflammation
Open Access
- 18 November 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (2) , 1617-1621
Abstract
Tissue inhibitor of metalloproteinase (TIMP)‐3 is a natural inhibitor of a range of enzymes that degrade connective tissue and are involved in the pathogenesis of conditions such as arthritis and cancer. We describe here the engineering of TIMP‐3 using a novel drug‐delivery system known as the ‘LAP technology’. This involves creating therapeutic proteins in fusion with the latency‐associated peptide (LAP) from the cytokine TGF‐? to generate proteins that are biologically inactive until cleavage of the LAP to release the therapy. LAP‐TIMP‐3 was successfully expressed in mammalian cells and the presence of the LAP resulted in a 14‐fold increase in the quantity of recombinant TIMP‐3 produced. LAP‐TIMP‐3 was latent until release from the LAP by treatment with matrix metalloproteinase when it could inhibit proteases of the adamalysins and adamalysins with thrombospondin motifs families, but not matrix metalloproteinases, indicating that this version of TIMP‐3 is a more specific inhibitor than the native protein. There was sufficient protease activity in synovial fluid from human joints with osteoarthritis to release TIMP‐3 from the LAP fusion. These results demonstrate the potential for development of TIMP‐3 as a novel therapy for conditions where upregulation of catabolic enzymes are part of the pathology.Keywords
This publication has 14 references indexed in Scilit:
- A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic jointsAnnals of the Rheumatic Diseases, 2014
- Latent cytokines for targeted therapy of inflammatory disordersExpert Opinion on Drug Delivery, 2013
- Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-βExpert Opinion on Drug Delivery, 2013
- A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomasInvestigational New Drugs, 2007
- The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitorsCardiovascular Research, 2006
- Targeting cytokines to inflammation sitesNature Biotechnology, 2003
- TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)Journal of Biological Chemistry, 2001
- Tissue inhibitors of metalloproteinases: evolution, structure and functionBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Preclinical and Clinical Studies of MMP Inhibitors in CancerAnnals of the New York Academy of Sciences, 1999
- TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3FEBS Letters, 1998